Yamanouchi U.S.A., Inc. Names Robert E. Desjardins, M.D. President Of Research and Development

Apr 10, 2001, 01:00 ET from Yamanouchi Pharmaceutical Co., Ltd.

    PARAMUS, N.J., and TOKYO, April 10 /PRNewswire/ -- Yamanouchi U.S.A.,
 Inc., the United States clinical research division of Yamanouchi
 Pharmaceutical Co., Ltd., has named Robert E. Desjardins, M.D. as President of
 Research and Development effective immediately.  Dr. Desjardins replaces
 Gensei Kon, D.V.M., Ph.D., who has been promoted to Chief Operating
 Officer/Ethical, of Yamanouchi Group Holding, Inc.
     Dr. Desjardins joined Yamanouchi U.S.A. in September 1999, and has served
 in the company's top R&D leadership positions.  He was most recently Executive
 Vice President of Research and Development, where he was in charge of the
 overall development of the company's proprietary therapeutic products.  His
 responsibilities focused on the management of research, clinical development
 and regulatory affairs, including interaction with the Food and Drug
 Administration (FDA).  Further, Dr. Desjardins coordinated activities with
 Yamanouchi's Japanese and European research and development programs to
 maximize global research and development.
     "I am pleased to further expand my role at Yamanouchi during this exciting
 time of growth and lead their U.S. domestic R&D initiatives," said Dr.
 Desjardins.  "It is my intention to build upon our rich R&D pipeline and focus
 on clinical development programs in the United States that will support
 Yamanouchi's business objectives to broaden its presence here, becoming a
 truly global research-based pharmaceutical enterprise."
     Prior to his tenure with Yamanouchi U.S.A., Dr. Desjardins was Vice
 President of Clinical Research in the Medical Research Division of Lederle
 Laboratories.
     Dr. Desjardins began his career with the Walter Reed Army Institute of
 Research in the Antimalarial Drug Development Program.  He received his M.D.
 from the Stritch School of Medicine at Loyola University, and is a member of
 the American Medical Association and American Society of Clinical Pharmacology
 and Therapeutics.
 
     Yamanouchi U.S.A. R&D to Support Expanded American Business Operations
     Earlier this year, Yamanouchi announced the formation of Yamanouchi
 America, Inc., headquartered in Paramus, NJ.  The goal of the new business is
 to independently market Yamanouchi's key pharmaceutical products through a new
 sales network within the next few years.
     Under the leadership of Dr. Desjardins, Yamanouchi U.S.A., Inc. will focus
 its clinical development programs on a number of promising drug candidates for
 the Yamanouchi America, Inc. business, including: YM087 -- a treatment for
 heart failure and hyponatremia, YM872 -- a treatment for acute ischemic
 stroke, YM905 -- a treatment for urinary incontinence, and YM992 -- an oral
 antidepressant.
     "Dr. Desjardins' research and development organization will provide
 medical, clinical and regulatory affairs services and guidance to the new
 Yamanouchi business in the United States," said Nicholas L. Teti, President of
 Yamanouchi America, Inc.  "Together, our two divisions are developing the
 necessary power to enter the U.S. market with innovative products supported by
 a strong sales and marketing organization."
     Yamanouchi Pharmaceutical Co., Ltd. has always made an impact on the U.S.
 pharmaceutical market through its clinical development and the licensing of
 many well-known products.  Yamanouchi has licensed Cardene(R) (nicardipine) to
 Syntex/Roche, Pepcid(R) (famotidine) to Merck, Cefotan(R) (cefotetan) to
 Astra-Zeneca, Foradil(R) (formoterol) to Novartis, and Flomax(R) (tamsulosin)
 to Boehringer Ingelheim.
     Additionally, Yamanouchi's presence in the United States includes
 Yamanouchi Pharma Technologies, Inc. (YPT) Research Center on the grounds of
 the Stanford Research Park in Palo Alto, California, and Manufacturing Center
 in Norman, Oklahoma.  YPT is principally involved in the commercial
 development of the company's drug delivery technologies.
     Earlier this year, the company also established Yamanouchi Venture Capital
 LLC in Palo Alto, California, in order to expand and strengthen the Yamanouchi
 Group's investments in early stage biotechnology companies throughout the
 world.
 
     Yamanouchi U.S.A., Inc.
     Established in 1993, Yamanouchi U.S.A., Inc. engages in clinical product
 development and promotes Yamanouchi's pharmaceutical business in the United
 States.  Headquartered in Paramus, NJ, Yamanouchi U.S.A. works closely with
 its partners in Japan and Europe to continuously evaluate drug candidates,
 while supporting its U.S. operations and business developments.
 
     Yamanouchi Pharmaceutical Co., Ltd.
     Yamanouchi Pharmaceutical Co., Ltd., established in 1923 and headquartered
 in Tokyo, Japan, is the third largest pharmaceutical company in Japan.
 Yamanouchi is expanding its business base to Europe, the United States and
 Asia and employs more than 9,000 people worldwide.  As a research-based
 developer, manufacturer and marketer, Yamanouchi has introduced several world-
 class drugs to the international markets, including the H2 antagonist
 famotidine, the calcium antagonist nicardipine, and tamsulosin, a treatment
 for functional symptoms of benign prostatic hyperplasia.
 
 

SOURCE Yamanouchi Pharmaceutical Co., Ltd.
    PARAMUS, N.J., and TOKYO, April 10 /PRNewswire/ -- Yamanouchi U.S.A.,
 Inc., the United States clinical research division of Yamanouchi
 Pharmaceutical Co., Ltd., has named Robert E. Desjardins, M.D. as President of
 Research and Development effective immediately.  Dr. Desjardins replaces
 Gensei Kon, D.V.M., Ph.D., who has been promoted to Chief Operating
 Officer/Ethical, of Yamanouchi Group Holding, Inc.
     Dr. Desjardins joined Yamanouchi U.S.A. in September 1999, and has served
 in the company's top R&D leadership positions.  He was most recently Executive
 Vice President of Research and Development, where he was in charge of the
 overall development of the company's proprietary therapeutic products.  His
 responsibilities focused on the management of research, clinical development
 and regulatory affairs, including interaction with the Food and Drug
 Administration (FDA).  Further, Dr. Desjardins coordinated activities with
 Yamanouchi's Japanese and European research and development programs to
 maximize global research and development.
     "I am pleased to further expand my role at Yamanouchi during this exciting
 time of growth and lead their U.S. domestic R&D initiatives," said Dr.
 Desjardins.  "It is my intention to build upon our rich R&D pipeline and focus
 on clinical development programs in the United States that will support
 Yamanouchi's business objectives to broaden its presence here, becoming a
 truly global research-based pharmaceutical enterprise."
     Prior to his tenure with Yamanouchi U.S.A., Dr. Desjardins was Vice
 President of Clinical Research in the Medical Research Division of Lederle
 Laboratories.
     Dr. Desjardins began his career with the Walter Reed Army Institute of
 Research in the Antimalarial Drug Development Program.  He received his M.D.
 from the Stritch School of Medicine at Loyola University, and is a member of
 the American Medical Association and American Society of Clinical Pharmacology
 and Therapeutics.
 
     Yamanouchi U.S.A. R&D to Support Expanded American Business Operations
     Earlier this year, Yamanouchi announced the formation of Yamanouchi
 America, Inc., headquartered in Paramus, NJ.  The goal of the new business is
 to independently market Yamanouchi's key pharmaceutical products through a new
 sales network within the next few years.
     Under the leadership of Dr. Desjardins, Yamanouchi U.S.A., Inc. will focus
 its clinical development programs on a number of promising drug candidates for
 the Yamanouchi America, Inc. business, including: YM087 -- a treatment for
 heart failure and hyponatremia, YM872 -- a treatment for acute ischemic
 stroke, YM905 -- a treatment for urinary incontinence, and YM992 -- an oral
 antidepressant.
     "Dr. Desjardins' research and development organization will provide
 medical, clinical and regulatory affairs services and guidance to the new
 Yamanouchi business in the United States," said Nicholas L. Teti, President of
 Yamanouchi America, Inc.  "Together, our two divisions are developing the
 necessary power to enter the U.S. market with innovative products supported by
 a strong sales and marketing organization."
     Yamanouchi Pharmaceutical Co., Ltd. has always made an impact on the U.S.
 pharmaceutical market through its clinical development and the licensing of
 many well-known products.  Yamanouchi has licensed Cardene(R) (nicardipine) to
 Syntex/Roche, Pepcid(R) (famotidine) to Merck, Cefotan(R) (cefotetan) to
 Astra-Zeneca, Foradil(R) (formoterol) to Novartis, and Flomax(R) (tamsulosin)
 to Boehringer Ingelheim.
     Additionally, Yamanouchi's presence in the United States includes
 Yamanouchi Pharma Technologies, Inc. (YPT) Research Center on the grounds of
 the Stanford Research Park in Palo Alto, California, and Manufacturing Center
 in Norman, Oklahoma.  YPT is principally involved in the commercial
 development of the company's drug delivery technologies.
     Earlier this year, the company also established Yamanouchi Venture Capital
 LLC in Palo Alto, California, in order to expand and strengthen the Yamanouchi
 Group's investments in early stage biotechnology companies throughout the
 world.
 
     Yamanouchi U.S.A., Inc.
     Established in 1993, Yamanouchi U.S.A., Inc. engages in clinical product
 development and promotes Yamanouchi's pharmaceutical business in the United
 States.  Headquartered in Paramus, NJ, Yamanouchi U.S.A. works closely with
 its partners in Japan and Europe to continuously evaluate drug candidates,
 while supporting its U.S. operations and business developments.
 
     Yamanouchi Pharmaceutical Co., Ltd.
     Yamanouchi Pharmaceutical Co., Ltd., established in 1923 and headquartered
 in Tokyo, Japan, is the third largest pharmaceutical company in Japan.
 Yamanouchi is expanding its business base to Europe, the United States and
 Asia and employs more than 9,000 people worldwide.  As a research-based
 developer, manufacturer and marketer, Yamanouchi has introduced several world-
 class drugs to the international markets, including the H2 antagonist
 famotidine, the calcium antagonist nicardipine, and tamsulosin, a treatment
 for functional symptoms of benign prostatic hyperplasia.
 
 SOURCE  Yamanouchi Pharmaceutical Co., Ltd.